Skip to Main Content

Dr. Sandy Feng is a transplant surgeon who performs liver, kidney and pancreas transplants.

In her research, Feng studies transplantation tolerance, a transplant recipient's ability to maintain normal organ function with minimal or no use of immunosuppressive drugs. With funding from the National Institutes of Health, she has led several multicenter clinical trials to study tolerance in both adult and pediatric liver transplant recipients.

Feng is a graduate of Harvard College, where she received the prestigious Marshall Scholarship. She completed a doctorate in molecular biology at the University of Cambridge and earned her medical degree at Stanford University School of Medicine. She completed a general surgery residency at Brigham and Women's Hospital, followed by a transplant fellowship at UCSF.

Feng has held leadership positions in prominent professional societies and with the United Network for Organ Sharing. She has organized several national conferences addressing issues critical to the transplantation community, serves on the editorial board of the New England Journal of Medicine and is the editor-in-chief for the American Journal of Transplantation.

  • Education

    Stanford University School of Medicine, 1990

  • Residencies

    Brigham and Women's Hospital, General Surgery, 1995

  • Fellowships

    UCSF Medical Center, Transplant, 1998

  • Board Certifications

    Surgery, American Board of Surgery

  • Academic Title

    Professor

Where I see patients (3)

    Decorative Caduceus

    Liver Transplantation With Tregs at UCSF

    AEs will be attributed to alloantigen-reactive Tregs (arTreg) when the AE is reported with possible or related attribution to arTreg. Grading: According to the NCI Common Terminology Criteria for Adverse Events Manual [NCI-CTCAE ...

    Recruiting

    Decorative Caduceus

    Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

    Based on the reference set, create molecular classifier that predicts antibody mediated and T cell mediated rejection for next 200 biopsies

    Recruiting

    Share